Genmab A/S
GNMSF
$241.84
-$3.16-1.29%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 29.37% | -22.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.37% | -22.33% | |||
| Cost of Revenue | 35.71% | -12.79% | |||
| Gross Profit | 28.97% | -22.85% | |||
| SG&A Expenses | 14.29% | -29.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.21% | -11.65% | |||
| Operating Income | 91.49% | -41.97% | |||
| Income Before Tax | 73.36% | -52.60% | |||
| Income Tax Expenses | 77.55% | 241.10% | |||
| Earnings from Continuing Operations | 72.31% | -64.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 72.31% | -64.51% | |||
| EBIT | 91.49% | -41.97% | |||
| EBITDA | 86.00% | -40.58% | |||
| EPS Basic | 77.78% | -64.62% | |||
| Normalized Basic EPS | 73.63% | -57.40% | |||
| EPS Diluted | 77.70% | -64.39% | |||
| Normalized Diluted EPS | 73.55% | -57.12% | |||
| Average Basic Shares Outstanding | -3.08% | 0.31% | |||
| Average Diluted Shares Outstanding | -3.04% | -0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||